These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33212122)

  • 1. Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity: A Meta-analysis.
    Tsai CY; Yeh PT; Tsao PN; Chung YE; Chang YS; Lai TT
    Ophthalmology; 2021 Jun; 128(6):877-888. PubMed ID: 33212122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry?
    Celik P; Ayranci Sucakli I; Kara C; Petricli IS; Kavurt S; Celik IH; Bas AY; Demirel N
    J Matern Fetal Neonatal Med; 2022 Feb; 35(3):415-422. PubMed ID: 33618591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Meta-Analysis of Neurodevelopmental Outcomes following Intravitreal Bevacizumab for the Treatment of Retinopathy of Prematurity.
    Baiad AA; Kherani IZ; Popovic MM; Katsnelson G; Muni RH; Mireskandari K; Tehrani NN; Zhou TE; Kertes PJ
    Neonatology; 2023; 120(5):577-588. PubMed ID: 37487481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser.
    Raghuram K; Isaac M; Yang J; AlAli A; Mireskandari K; Ly LG; Kelly E; Banihani R; Shah PS; Tehrani N
    J Perinatol; 2019 Sep; 39(9):1300-1308. PubMed ID: 31341226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study.
    Fan YY; Huang YS; Huang CY; Hsu JF; Shih CP; Hwang YS; Yao TC; Lai CC; Wu WC
    Ophthalmology; 2019 Nov; 126(11):1567-1577. PubMed ID: 30954553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment.
    Lien R; Yu MH; Hsu KH; Liao PJ; Chen YP; Lai CC; Wu WC
    PLoS One; 2016; 11(1):e0148019. PubMed ID: 26815000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
    Araz-Ersan B; Kir N; Tuncer S; Aydinoglu-Candan O; Yildiz-Inec D; Akdogan B; Ekici B; Demirel A; Ozmen M
    Curr Eye Res; 2015 May; 40(6):585-91. PubMed ID: 25025864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP.
    Rodriguez SH; Peyton C; Lewis K; Andrews B; Greenwald MJ; Schreiber MD; Msall ME; Blair MP
    Ophthalmic Surg Lasers Imaging Retina; 2019 Jun; 50(6):337-343. PubMed ID: 31233150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity.
    Morin J; Luu TM; Superstein R; Ospina LH; Lefebvre F; Simard MN; Shah V; Shah PS; Kelly EN;
    Pediatrics; 2016 Apr; 137(4):. PubMed ID: 27244705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodevelopmental Outcomes for Retinopathy of Prematurity: A Taiwan Premature Infant Follow-up Network Database Study.
    Chiang MC; Chen YT; Kang EY; Chen KJ; Wang NK; Liu L; Chen YP; Hwang YS; Lai CC; Wu WC
    Am J Ophthalmol; 2023 Mar; 247():170-180. PubMed ID: 36343698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurodevelopmental Outcomes Following Intravitreal Bevacizumab With Laser Versus Laser Photocoagulation Alone for Retinopathy of Prematurity.
    Ahmed K; Ali AS; Delwadia N; Greven MA
    Ophthalmic Surg Lasers Imaging Retina; 2020 Apr; 51(4):220-224. PubMed ID: 32348538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab for Retinopathy of Prematurity: 2-Year Neurodevelopmental Follow-up.
    Zayek M; Parker K; Rydzewska M; Rifai A; Bhat R; Eyal F
    Am J Perinatol; 2021 Sep; 38(11):1158-1166. PubMed ID: 32446264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection.
    Milani AE; Arasteh A; Saeedi-Maleki Z; Niyousha MR; Sahebazamani MA; Brumandpur F
    BMC Ophthalmol; 2024 Jun; 24(1):265. PubMed ID: 38907228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment.
    Chang YS; Chen YT; Lai TT; Chou HC; Chen CY; Hsieh WS; Yang CM; Yeh PT; Tsao PN
    PLoS One; 2019; 14(10):e0223972. PubMed ID: 31618256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
    Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
    Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
    Akdogan M; Cevik SG; Sahin O
    Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.